These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21862004)

  • 1. GI perforation associated with bevacizumab.
    Yoon SS; Rivera R; Shah A; Ozden N
    Gastrointest Endosc; 2012 Jun; 75(6):1286-7. PubMed ID: 21862004
    [No Abstract]   [Full Text] [Related]  

  • 2. Endoscopic management of colonic perforation owing to angiogenesis inhibitors.
    Ezzedine S; Bege T; Berdah S; Vitton V; Grimaud JC; Barthet M
    Surg Laparosc Endosc Percutan Tech; 2010 Dec; 20(6):e230-2. PubMed ID: 21150409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab-induced bowel perforation.
    Sliesoraitis S; Tawfik B
    J Am Osteopath Assoc; 2011 Jul; 111(7):437-41. PubMed ID: 21803880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Surgical management of bevacizumab-associated peritonitis due to perforation].
    Kube R; Meyer F; Bien N; Schmidt C; Mroczkowski P; Dalicho S; Lippert H
    Zentralbl Chir; 2009 Sep; 134(5):462-7. PubMed ID: 19757347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diaphragmatic rupture, a new complication of Bevacizumab.
    Lacaze L; Scotté M
    Eur J Surg Oncol; 2012 Nov; 38(11):1079-81. PubMed ID: 22818843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
    Han ES; Monk BJ
    Gynecol Oncol; 2007 Apr; 105(1):3-6. PubMed ID: 17383545
    [No Abstract]   [Full Text] [Related]  

  • 7. Gastrointestinal perforation due to bevacizumab in colorectal cancer.
    Saif MW; Elfiky A; Salem RR
    Ann Surg Oncol; 2007 Jun; 14(6):1860-9. PubMed ID: 17356952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients.
    Borofsky SE; Levine MS; Rubesin SE; Tanyi JL; Chu CS; Lev-Toaff AS
    Abdom Imaging; 2013 Apr; 38(2):265-72. PubMed ID: 22627832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case of delayed colonic perforation after metallic stent placement for advanced descending colon cancer during bevacizumab-based chemotherapy].
    Tanaka I; Hisai H; Miyazaki E; Ono M; Maeda Y; Sato M; Kawasaki R; Gyobu H; Nakajima S; Yamada S; Muramatsu H
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2319-21. PubMed ID: 22202368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal perforation in metastatic carcinoma: a complication of bevacizumab therapy.
    Collins D; Ridgway PF; Winter DC; Fennelly D; Evoy D
    Eur J Surg Oncol; 2009 Apr; 35(4):444-6. PubMed ID: 18417314
    [No Abstract]   [Full Text] [Related]  

  • 11. Infusion of bevacizumab increases the risk of intestinal perforation: results on a series of 143 patients consecutively treated.
    Borzomati D; Nappo G; Valeri S; Vincenzi B; Ripetti V; Coppola R
    Updates Surg; 2013 Jun; 65(2):121-4. PubMed ID: 23532741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.
    Kabbinavar FF; Flynn PJ; Kozloff M; Ashby MA; Sing A; Barr CE; Grothey A
    Eur J Cancer; 2012 May; 48(8):1126-32. PubMed ID: 22424880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
    Heinzerling JH; Huerta S
    Curr Surg; 2006; 63(5):334-7. PubMed ID: 16971205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrobulbar optic neuritis in a bevacizumab-treated patient with metastatic breast cancer.
    Zhou Y; Zhang Y; Yang X; Fan L; Jiang J
    Breast J; 2012 Sep; 18(5):502-3. PubMed ID: 22891618
    [No Abstract]   [Full Text] [Related]  

  • 15. Bevacizumab-associated reversible hypotension.
    Iqbal K; Chu Q; Mei Q; Chen Y
    Clin Oncol (R Coll Radiol); 2007 Dec; 19(10):800-1. PubMed ID: 17825542
    [No Abstract]   [Full Text] [Related]  

  • 16. Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer.
    Sclafani F; Giuseppe G; Mezynksi J; Collins C; Crown J
    J Clin Oncol; 2012 Sep; 30(26):e257-9. PubMed ID: 22649141
    [No Abstract]   [Full Text] [Related]  

  • 17. [Generation mechanisms and management strategies of adverse reactions to Bevacizumab during cancer treatment].
    Ge FJ; Xu JM
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):481-6. PubMed ID: 21029688
    [No Abstract]   [Full Text] [Related]  

  • 18. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers.
    Abu-Hejleh T; Mezhir JJ; Goodheart MJ; Halfdanarson TR
    Curr Oncol Rep; 2012 Aug; 14(4):277-84. PubMed ID: 22532266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of metachronous gastrointestinal perforation of a patient with metastatic rectal cancer during treatment with bevacizumab-based chemotherapy].
    Sadatomo A; Koinuma K; Miki A; Horie H; Yasuda Y
    Gan To Kagaku Ryoho; 2013 Jul; 40(7):943-5. PubMed ID: 23863742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases.
    Lecarpentier E; Ouaffi L; Mir O; Berveiller P; Maurel M; Pujade-Lauraine E; Bouillot JL; Veyrie N
    Invest New Drugs; 2011 Dec; 29(6):1500-3. PubMed ID: 20676743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.